Fused Or Hybrid Cell, Per Se Patents (Class 435/346)
  • Cleavage site blocking antibody to prohormone proteins and uses thereof
    Patent number: 5677182
    Abstract: Cleavage site blocking antibody that binds to prohormones, preferable Tumor Necrosis Factor, thereby preventing the formation of prohormone fragment(s) by proteolysis of the prohormone, and uses of the antibody including prophylactic and therapeutic methods to treat disease, and diagnostic assays for determining the amount of the prohormone and prohormone fragments present in a patients body.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: October 14, 1997
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Carl Perez
  • Immortalized epithelial cell lines
    Patent number: 5643782
    Abstract: An immortalized epithelial lens cell line obtained from human lens epithelial cells infected with hybride adenovirus/SV40 (Ad12-SV40), and methods for making and using the cell line are disclosed.
    Type: Grant
    Filed: August 23, 1993
    Date of Patent: July 1, 1997
    Assignee: Washington University in St. Louis
    Inventors: Usha P. Andley, Timothy P. Fleming
  • Method for purifying chromosomes and hybrid muntjac cell lines containing foreign chromosomes
    Patent number: 5635376
    Abstract: Introducing a chromosome or chromosome fragment having a size of 25 to 500 Mb and containing a selectable marker into a female muntjac cell which has been immortalized with a nonviral vector, a chemical treatment, or a radiation treatment permits the easy purification of the chromosome or chromosome fragment.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: June 3, 1997
    Assignee: The Regents of the University of Michigan
    Inventors: Andrew P. Feinberg, Jae-Yong Lee
  • Chimeric sheets of epithelial cells
    Patent number: 5610007
    Abstract: A process for culturing and generating a chimeric cell culture, in particular chimeric epithelium, is disclosed. The chimeric epithelium can be used to treat skin trauma such as burn victims. Autologous epithelial grafts have been used on burn patients although this requires that the patient's cells are cultured and expanded in vitro which generally takes four to five weeks. The chimeric epithelium of the present invention is composed of cells that are both autologous and allogeneic to the host. Therefore, the allogeneic cells can be maintained in a cell bank and co-cultured with autologous host cells when needed. This significantly reduces the time required (by up to 50%) for autologous cell expansion and culture prior to grafting. Furthermore, it has been demonstrated that the allogeneic cells are passively eliminated from the graft without rejection of the total graft.
    Type: Grant
    Filed: January 21, 1993
    Date of Patent: March 11, 1997
    Assignee: Universite Laval
    Inventors: Fran.cedilla.ois A. Auger, Mahmoud Rouabhia, Louis Lafleur, Lucie Germain
  • Cell line TriH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma
    Patent number: 5602027
    Abstract: A new cell line TriH8 is obtained by fusing a particular sub-clone, A431c, of the human epidermoid carcinoma cell line A431 with the TOS/H8 (human/human) hybridoma. Fused cell TriH8 has been deposited under FRI accession number FERM BP-4452. The fused cell is capable of proliferating in basal medium without addition of serum or growth factor. The cell line is more effective in producing antibody (IgM) than the donor cell TOS/H8.
    Type: Grant
    Filed: December 16, 1992
    Date of Patent: February 11, 1997
    Assignee: Yoshihide Hagiwara
    Inventors: Hideaki Hagiwara, Hideo Yuasa